Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Broadcom Inc (AVGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Broadcom Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Broadcom Inc trades at $389.79 (market cap $1.76T). The key difference: Broadcom Inc is far larger — about 392× ACADIA Pharmaceuticals Inc.'s market cap, and Broadcom Inc pays a 0.7% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AVGO | |
|---|---|---|
Market Cap | $4.49B | $1.76T |
Sector | Health | Technology |
52-Week High | $28.06 | $481.57 |
52-Week Low | $20.06 | $271.80 |
Enterprise Value | $3.69B | $1.81T |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Broadcom (AVGO) trades at $370.78, up 2.87% today but remains in a bearish technical trend, 25% below its 52-week high. The company demonstrates strong fundamentals with Q1 2026 EPS beating estimates at $2.44 and robust revenue growth from $51.6B in 2024 to $63.9B in 2025. Recent news highlights a strategic partnership extension with Apple through 2031 for custom AI chips, providing long-term revenue visibility amid a challenging market environment for semiconductor stocks.
AVGO presents a compelling investment case with strong analyst support (88% buy ratings) and a $510.43 consensus price target representing 38% upside. However, elevated valuation multiples (P/E 62.21, P/S 24.17) and technical bearish signals warrant caution. The key opportunity lies in AVGO's AI semiconductor growth (143% YoY to $10.8B last quarter) while risks include market volatility and competitive pressures in the chip sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
